Improved Outcome When B-Cell Lymphoma Is Treated with Combinations of Immunoliposomal Anticancer Drugs Targeted to Both the CD19 and CD20 Epitopes

Clinical Cancer Research

Volumn 10, Issue 7, 2004, Pages 2530-2537

  Sapra, Puja ^a   Allen, Theresa M ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD19 ANTIGEN; CD20 ANTIGEN; DOXORUBICIN; IMMUNOLIPOSOME; SPHINGOMYELIN; UNCLASSIFIED DRUG; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B CELL LYMPHOMA; CONTROLLED STUDY; DRUG FORMULATION; DRUG TARGETING; FEMALE; ISOTOPE LABELING; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; SURVIVAL RATE; TUMOR XENOGRAFT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, MONOCLONAL; ANTIGENS, CD19; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; CELL SURVIVAL; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG CARRIERS; EPITOPES; FEMALE; IMMUNOTHERAPY; LIGANDS; LIPOSOMES; LYMPHOMA, B-CELL; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; TREATMENT OUTCOME; VINCRISTINE;

EID: 1842478453     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0376     Document Type: Article

References (40)

1. Sapra P, Allen TM. Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Cancer Res 2002;62:7190-4.
2. Lopes de Menezes DE, Pilarski LM, Allen TM. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res 1998;58:3320-30.
3. 2-mediated melanoma cell targeting and cytotoxicity of liposome-entrapped fenretinide. Int J Cancer 1999;81:268-74.
4. Sugano M, Egilmez NK, Yokota SJ, et al. Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice. Cancer Res 2000;60:6942-9.
5. Park JW, Hong K, Kirpotin DB, et al. Anti-HER2 immunoliposomes: Enhanced efficacy attributable to targeted delivery. Clin Cancer Res 2002;8:1172-81.
6. Pastorino F, Brignole C, Marimpietri D, et al. Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice. Cancer Res 2003;63:86-92.
7. Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nature Reviews Cancer 2002;2:750-63.
8. Mastrobattista E, Koning G, Storm G. Immunoliposomes for the targeted delivery of antitumor drugs. Adv Drug Delivery Reviews 1999;40:103-27.
9. Scheinberg DA, Sgouros G, Junghans RP. Antibody-based immunotherapies for cancer. In: Chabner BA, Longo DL, editors. Cancer chemotherapy and biotherapy, 3 edition. Philadelphia: Lippincott Williams and Wilkins; 2001. p. 850-890.
10. Milenic DE. Monoclonal antibody-based therapy strategies: providing options for the cancer patient. Curr Pharm Des 2002;8:1749-64.
11. Levy R, Miller RA. Therapy of lymphoma directed at idiotypes. J Natl Cancer Inst Monogr 1990;10.
12. Engert A, Gottstein C, Bohlen H, et al. Cocktails of Ricin A-chain immunotoxins against different antigens on hodgkin and stemberg-reed calls have superior antitumor effects against H-RS cells in vitro and solid hodgkin tumors in mice. Int J Cancer 1995;63:304-9.
13. Flavell DJ, Boehm DA, Emery L, Noss A, Ramsay A, Flavell SU. Therapy of human B-cell lymphoma bearing SCID mice is more effective with anti-CD19- and anti-CD38-saporin immunotoxins used in combination than with either immunotoxin used alone. Int J Cancer 1995;62:337-44.
14. Flavell DJ, Noss A, Pulford KAF, Ling N, Flavell SU. Systemic therapy with 3BIT, a triple combination cocktail of anti-CD19, -CD22, and -CD38-saporin immunotoxins, is curative of human B-cell lymphoma in severe combined immunodeficient mice. Cancer Res 1997; 57:4824-9.
15. Flavell DJ, Boehm DA, Noss A, Warnes SL, Flavell SU. Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-saporin immunotoxins is significantly better than therapy with each individual immunotoxin. Br J Cancer 2001;84: 571-8.
16. Ghetie M-A, Tucker K, Richardson J, Uhr JW, Vitetta ES. Eradication of minimal disease in SCID mice with disseminated Daudi Lymhoma using chemotherapy and an immunotoxin cocktail. Blood 1994;84:702-7.
17. Ghetie M-A, Podar EM, Gordan BE, Pantazis P, Uhr JW, Vitetta ES. Combination immunotoxin treatment and chemotherapy in SCID mice with advanced, disseminated daudi lymhoma. Int J Cancer 1996; 68:93-6.
18. Press OW, Farr AG, Borroz KI, Andersen SK, Martin PJ. Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. Cancer Res 1989;49:4906-12.
19. Vangeepuram N, Ong GL, Mattes MJ. Processing of antibodies bound to B-cell lymphomas and lymphoblastoid cell lines. Cancer 1997;80:2425-30.
20. Goren D, Horowitz AT, Zalipsky S, Woodle MC, Yarden Y, Gabizon A. Targeting of stealth liposomes to erB-2 (Her/2) receptor: in vitro and in vivo studies. Br J Cancer 1996;74:1749-56.
21. Vingerhoeds MH, Steerenberg PA, Hendriks JJGW, et al. Immunoliposome-mediated targeting of doxorubicin to human ovarian carcinoma in vitro and in vivo. Br J Cancer 1996;74:1023-9.
22. Allen TM, Hansen CB, Martin F, Redemann C, Yau-Young A. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta 1991;1066:29-36.
23. Kirpotin D, Park JW, Hong K, et al. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry 1997;36:66-75.
24. Zola H, Macardle PJ, Bradford T, Weedon H, Yasui H, Kurosawa Y. Preparation and characterization of a chimeric CD19 monoclonal antibody. Immunol Cell Biol 1991;69:411-22.
25. Iden DL, Allen TM. In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion technique. Biochim Biophys Acta 2001;1513: 207-16.
26. Bolotin EM, Cohen R, Bar LK, Emanuel SN, Lasic DD, Barenholz Y. Ammonium sulphate gradients for efficient and stable remote loading of amphipathic weak bases into liposomes and ligandosomes. J Liposome Res 1994;4:455-79.
27. Boman NL, Masin D, Mayer LD, Cullis PR, Bally MB. Liposomal vincristine which exhibits increased drug retention and increased circulation longevity cures mice bearing P388 tumors. Cancer Res 1994;54: 2830-3.
28. Mayer LD, Bally MB, Loughrey H, Masin D, Cullis PR. Liposomal vincristine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors. Cancer Res 1990;50:575-9.
29. Abrahamson DR, Fearon DT. Endocytosis of the C3b receptor of complement within coated pits in human polymorphonuclear leukocytes and monocytes. Lab Investig 1983;48:162-8.
30. Uckun FM, Jaszcz W, Ambrus JL, et al. Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins. Blood 1988;71:13-29.
31. van Oosterhout YVJM, van den Herik-Oudijk IE, Wessels HMC, de Witte T, van de Winkel JGJ, Preijers, FWMB. Effect of isotype on internalization and cytotoxicity of CD19-ricin A immunotoxins. Cancer Res 1994;54:3527-32.
32. Sapra P, Moase EH, Ma J, Allen TM. Improved therapeutic responses in a xenograft model of human B-lymphoma (Namalwa) for liposomal vincristine versus liposomal doxorubicin targeted via anti-CD19 IgG2a or Fab' fragments. Clin Cancer Res. 2004;10:1100-1111.
33. Lopes de Menezes DE, Kirchmeier MJ, Gagne J-F, Pilarski LM, Allen TM. Cellular trafficking and cytotoxicity of anti-CD19-targeted liposomal doxorubicin in B lymphoma cells. J Liposome Res 1999;9: 199-228.
34. Ishida T, Kirchmeier MJ, Moase EH, Zalipsky S, Allen TM. Targeted delivery and triggered release of liposomal doxorubicin enhances cytotoxicity against human B lymphoma cells. Biochim Biophys Acta 2001;1515:144-58.
35. Kirchmeier MJ, Ishida T, Chevrette J, Allen TM. Correlations between the rate of intracellular release of endocytosed liposomal doxorubicin and cytotoxicity as determined by a new assay. J Liposome Res 2001;11:15-29.
36. Starling JJ, Hinson NA, Marder P, Maciak RS, Laguzza BC. Rapid internalization of antigen-immunoconjugate complexes is not required for anti-tumor activity of monoclonal antibody-drug conjugates. Antibody, Immunoconjugates and Radiopharmaceuticals 1988;1:311-24.
37. Starling JJ, Maciak RS, Law KL, et al. In vivo antitumor activity of monoclonal antibody-vinca alkaloid immunoconjugate directed against a solid tumor membrane antigen characterized by heterogenous expression and nonintemalization of antibody-antigen complexes Cancer Res 1991;51:2965-72.
38. Braslawsky GS, Kadow K, Knipe J, McGoff K, Edson M, Kaneko T. Adriamycin(hydrazone)-antibody conjugates require internalization and intracellular acid hydrolysis for antitumor activity. Cancer Immunol. Immunother 1991;33:367-74.
39. Wahl AF, Cerveny CG, Klussman K, et al. Anti-cancer activity of high-potency anti-CD20 antibody-drug conjugates. Proc Am Assoc Cancer Res 2003;44:175-6.
40. Hamm-Alvarez SF, Sonee M, Loran-Goss K, Shen WC. Paclitaxel and nocodazole differentially alter endocytosis in cultured cells. Pharm Res 1996;13:1647-56.